Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

  • Etude concernée: IFCT-1103
  • Auteurs / Authors: Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hiret S, Dixmier A, Renault PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, Besse B
  • Journal / Conference: European Journal of Cancer
  • Année / Year: 2020
  • PMID: 32276179
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/32276179/
  • PDF: IFCT-1103_ULTIMATE_EJC_Publication.pdf